Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine in advanced marginal zone B-cell lymphoma
NCT00337259Phase 2Terminated
- Sponsor
- Asan Medical Center
- Start
- Jun 2006
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine in marginal zone B-cell lymphoma (MZL), sponsored by Asan Medical Center. Primary endpoint: Overall Response Rate. Started Jun 2006; status: terminated.
02
Drugs
gemcitabine
03
Conditions
marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on NCT00337259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00337259.